Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896576 | 0.90 | HTT (0.46) | KMT2AGRM5MAPTALDH1A1NPSR1 | |
| SCHEMBL4892539 | 0.88 | GAA (0.43) | KMT2AMAPTALDH1A1NPSR1CCKBR | |
| SCHEMBL14087769 | 0.88 | ALDH1A1 (0.42) | KMT2AGRM5ALDH1A1NPSR1TSHR | |
| SCHEMBL4884230 | 0.87 | MAPT (0.43) | KMT2AGRM5MAPTALDH1A1NPSR1 | |
| SCHEMBL4892985 | 0.87 | ALDH1A1 (0.52) | KMT2AMAPTALDH1A1NPSR1KDM4E | |
| SCHEMBL4883870 | 0.83 | ALDH1A1 (0.48) | KMT2AALDH1A1NPSR1KDM4ECCKBR | |
| SCHEMBL4887551 | 0.82 | ALDH1A1 (0.43) | KMT2AALDH1A1NPSR1TSHRKDM4E | |
| SCHEMBL4892536 | 0.82 | ALDH1A1 (0.54) | KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL14087797 | 0.80 | HPGD (0.43) | MAPTALDH1A1NPSR1 | |
| SCHEMBL14087801 | 0.79 | ALDH1A1 (0.42) | MAPTALDH1A1NPSR1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | KMT2A 2650/4885GRM5 3835/4885MAPT 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.